
1615 IGN





600 South Avenue West . Westfield, New Jersey 07090 908.654.5000 . Fax 908.654.7866 . www.ldlkm.com

PATENTS, TRADEMARKS, COPYRIGHTS & UNFAIR COMPETITION

February 9, 2006

Commissioner For Patents
Office of Initial Patent Examination
Customer Service Center
P.O. Box 1450
Alexandria, VA 22313-1450

Re:

Our File: SEDERM 3.3-011

Appln. No. 10/525,985

Filing Date: September 15, 2005

Group Art Unit: 1615

Dear Sir:

We are enclosing herewith copies of the filing receipt, executed Declaration and Application Data Sheet for the above-identified patent application.

Please note that the third (3rd) word of the *Title* should read --der<u>iv</u>ed--, not "dervied."


Kindly issue a corrected filing receipt for the above-identified application as soon as possible.

Sincerely yours,

LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP

ARNOLD H. KRUMHOLZ Reg. No. 25,428

AHK/ls Enclosures



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	 ATTY DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/525,985	09/15/2005	1615	2290	SEDERM3.3-011	 1	21	4

CONFIRMATION NO. 4999

000530 LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK 600 SOUTH AVENUE WEST

WESTFIELD, NJ 07090

FILING RECEIPT

OC00000017938944

Date Mailed: 01/30/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Karl Lintner, Rambouillet, FRANCE;

Power of Attorney: The patent practitioners associated with Customer Number 000530.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/FR03/02400 07/29/2003

Foreign Applications

FRANCE 02/10810 08/30/2002

Projected Publication Date: 05/11/2006

Non-Publication Request: No

Early Publication Request: No

LDLK&M

FEB 0 7 2006

Title

Novel Molecules dervied from noraporphine

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject

matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



Application Information

Application Type:: Regular

Subject Matter:: Utility

Suggested Group Art Unit:: N/A

CD-ROM or CD-R?:: None

Sequence submission?:: None

Computer Readable Form (CRF)?:: No

Title:: NOVEL MOLECULES DERIVED FROM

NORAPORPHINE

Attorney Docket Number:: SEDERM 3.3-011

Request for Early Publication?:: No

Request for Non-Publication?:: No

Suggested Drawing Figure:: 1

Total Drawing Sheets:: 1

Small Entity?:: No

Petition included?:: No

Secrecy Order in Parent Appl.?:: No

Applicant Information

Applicant Authority Type:: Inventor

Primary Citizenship Country:: France

Status:: Full Capacity

Given Name:: Karl

Family Name:: Lintner

City of Residence:: Rambouillet

Country of Residence:: France

Street of mailing address:: 2, rue du Manège

City of mailing address:: Rambouillet

Country of mailing address:: France

Postal or Zip Code of mailing address:: F-78120

Correspondence Information

Correspondence Customer Number::

000530

Representative Information

Representative Customer Number::

000530

Domestic Priority Information

Application:: Co	ontinuity Type::	Parent Application::	Parent Filing Date::
This Application Na	ational Stage of	PCT/FR2003/002400	07/29/03

Foreign Priority Information

Country::	Application number::	Filing Date::	Priority Claimed::
France	02/10810	08/30/02	Yes

Assignee Information

Assignee name::

SEDERMA SAS

Street of mailing address::

29 rue du Chemin Vert - BP 33

City of mailing address::

Le Perray-en-Yvelines cedex

Country of mailing address::

France

Postal or Zip Code of mailing address::

F-78612

•	•				+ +,
•					
40		•			
				. •	• • •
(بي 60)		:		· · · · · .	
Sease type a plus sign (+)	inside this box +			hrough 10/31/200:	
A-7		U.S. Patent and T red to respond to a collection of	rademark Office; U information unless i	I.S. DEPARTMEN it contains a valid (IT OF COMMERCE OMB control number.
	N FOR UTILITY OR	Attorney Docket Nur	nber SEDE	RM 3.3-011	
	the state of the s	First Named Inventor Karl Lintner			
		COMPLETE IF KNOWN			
(37 (Application Number	Not Yet Assi		
Declaration	X Declaration	Filing Date	Concurrently	y Herewith	
Submitted with Initial OR	Submitted after Initial Filing (surcharge	Group Art Unit	N/A		
Filing	(37 CFR 1.16 (e)) required)	Examiner Name	Not Yet Assi	igned	
		<u> </u>	<u> </u>		
	•				
1	the state of the s	•			
I believe I am the origina invention entitled:	al and first inventor of the subject	t matter which is claimed a	and for which a p	patent is sought	on the
			•		
NOVEL MOLEC	ULES DERIVED FROM N	ORAPORPHINE			
	· · · · · · · · · · · · · · · · · · ·				
the specification of w		Title of the Invention)			
()	•			·	
OR					
X was filed on (M	M/DD/YYYY) 07/29/20	03 as United States	Application Nu	mber or PCT I	nternational
Application No.	CT/FR2003/002400 and	was amended on (MM/I	O (YYYNac	2/25/2005	(if applicable).
			itified specification	on, including the	e claims, as
continuation-in-part app	lications, material information w	hich became available bet	s defined in 37 C ween the filing d	FR 1.56, included the prior	ding for application and
inventor's or plant breed country other than the U application for patent, in	ler's rights certificate(s), or 365 Inited States of America, listed t ventor's or plant breeder's right	(a) of any PCT internations below and have also identi- s certificate(s), or of any P	al application whi fied below, by ch	nich designated hecking the box	at least one c, any foreign
Prior Foreign		1	Priority	Certified Co	opy Attached?
Application Number(s)	Country	(MM/DD/YYYY)	Not Claimed	YES	NO
02/10810	FR	08/30/2002			×
ī					
	DECLARATIO PATENT (37 (Declaration Submitted with Initial With Initial Filing As a below named i My residence, mailing a I believe I am the original invention entitled: NOVEL MOLEC the specification of w is attached her OR X was filed on (M Application No. P I hereby state that I have amended by any amend I acknowledge the duty continuation-in-part app the national or PCT inte I hereby claim foreign point inventor's or plant breed country other than the U application for patent, in before that of the applic Prior Foreign Application Number(s)	DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) Declaration Submitted with Initial Filing Submitted after Initial Filing Submitted submitted with Initial Filing Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required) As a below named inventor, I hereby declare to the subject invention entitled: NOVEL MOLECULES DERIVED FROM Notes that I have reviewed and understand the amended by any amendment specifically referred to about 1 acknowledge the duty to disclose information which is continuation-in-part applications, material information with an attended or PCT international filing date of the continuation for patent, inventor's or plant breeder's rights certificate(s), or 365 country other than the United States of America, listed the application for patent, inventor's or plant breeder's rights before that of the application on which priority is claimed Prior Foreign Application Number(s) Country	DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) Declaration Submitted with Initial Filing As a below named inventor, I hereby declare that: My residence, mailing address, and clitzenship are as stated below next to my nar I believe I am the original and first inventor of the subject matter which is claimed a invention entitled: NOVEL MOLECULES DERIVED FROM NORAPORPHINE the specification No. PCT/FR2003/002400 I acknowledge the duty to disclose information which became available bet the national or PCT international filing date of the continuation-in-part applications, material information which is material to patentability as continuation-in-part applications, material information which is material to patentability as continuation-in-part applications, material information which became available bet the national or PCT international filing date of the continuation-in-part applications. Inventor's or plant breeder's rights certificate(s), or 365 (a) of any PCT international prior for patent, inventor's or plant breeder's rights certificate(s), or of any Perior Foreign Application Number(s) Attorney Docket Nur First Named Inventor Capplication Submitted after Initial Filing Date Group Art Unit Examiner Name Filing Date Attorney Docket Nur First Named Inventor Filing Date (MM/DD/YYY)	Approved for use the funder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless is the Paperwork Reduction of Institution (37 CFR 1.63) Declaration Submitted Submitted after Initial Filting Date Concurrently Group Art Unit Examiner Name Not Yet Ass As a below named inventor, I hereby declare that: Wy residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original and first inventor of the subject matter which is claimed and for which a princention entitled: NOVEL MOLECULES DERIVED FROM NORAPORPHINE (Title of the Invention) the specification of which is attached hereto OR X was filed on (MM/DD/YYYY) O7/29/2003 as United States Application Nu Application No. PCT/FR2003/002400 I hereby state that I have reviewed and understand the contents of the above identified specification are available between the filling of the national or PCT international filing date of the continuation-in-part application. I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign a inventor's or plant breeder's rights certificate(s), or of any PCT international application on which priority is claimed. Prior Foreign Application App	Approved for use through 10/31/200 Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unitess it contains a valid to Trademark Officia; U.S. DePart MENT APPLICATION TORATION TORATION (37 CFR 1.63) Declaration Declaration Submitted with Initial Filing (surcharge (37 CFR 1.66)) As a below named inventor, I hereby declare that: My residence, mailing address, and clibzenship are as stated below next to my name. I believe I am the original and first inventor of the subject matter which is claimed and for which a patent is sought invention entitled: NOVEL MOLECULES DERIVED FROM NORAPORPHINE Thereby state that I have reviewed and understand the contents of the above identified specification, including the amended by any amendment specifically referred to above. I acknowledge the duty to disclose information which became available between the filing date of the prior the national or PCT international filing date of the continuation-in-part applications, material information which became available between the filing date of the prior the national or PCT international filing date of the continuation-in-part applications, material information which became available between the filing date of the prior the national or PCT international filing date of the continuation-in-part application which designated country other than the United States of America, listed below and have also identified below which designated country other than the United States of America, listed below and have also identified below which well application in which bedore that of the application on which priority is claimed. Prior Foreign Application in which periority is claimed. Prior Foreign Priority Denefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application have before that of the application on which priority is claimed. Prior Foreign Application in which designated country other than the United States of America, listed below and have also identified below. We

Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

PTO/SB/01 (03-01)

Approved for use through 10/31/2002. OMB 0551-0032 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Please type a plus sign (+) inside this box -Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. **DECLARATION** — Utility or Design Patent Application POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Customer Number 000530 000530 **Customer Number** OR Correspondence address below Direct all correspondence to: or Bar Code Label Name Address ZIP State City Telephone Country I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. A petition has been filed for this unsigned inventor NAME OF SOLE OR FIRST INVENTOR: **Family Name** Lintner Given Name Karl (first and middle [if any]) or Surname inventor's Signature France Rambouillet France Citizenship Residence: City Mailing Address: 2, rue du Manège France F-78120 Rambouillet Country City A petition has been filed for this unsigned inventor NAME OF SECOND INVENTOR: Family Name Given Name or Surname (first and middle [if any]) inventor's Date Signature Citizenship Residence: City State Country Mailing Address: City

LD-537\

Additional inventors are being named on the

supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto.